annexin A3

From August 18th 2026, GtoPdb will require users to register to use the website. Please see our blog post for more information.

Home
Ligands
annexin A3 (Human)

GtoPdb Ligand ID: 13777

Synonyms: annexin III | calcimedin 35-alpha | inositol 1,2-cyclic phosphate 2-phosphohydrolase (EC 3.1.4.43) | lipocortin III | placental anticoagulant protein III

Compound class: Endogenous peptide in human, mouse or rat

Comment: Annexin A3 (ANXA3) is one member of a family of intracellular calcium-dependent phospholipid-binding proteins (13 genes in humans). It regulates cellular growth and signal transduction pathways via inhibition of phopholipase A2. This activity modulates the conversion of inositol 1,2-cyclic phosphate to inositol 1-phosphate.
Pathogenic effects of ANXA3 have been reported in the development of cancers [2,4], in particular triple-negative breast cancer (TNBC) [5]. Pharmacological modulation of ANXA3 is therefore of interest for the development of TNBC therapeutics.

Species: Human

References
1. Liang Y, Min D, Fan H, Liu K, Tu J, He X, Liu B, Zhou L, Liu S, Sun X. (2023) Discovery of a first-in-class ANXA3 degrader for the treatment of triple-negative breast cancer. Acta Pharm Sin B, 13 (4): 1686-1698. [PMID:37139408]
2. Liu C, Li N, Liu G, Feng X. (2021) Annexin A3 and cancer. Oncol Lett, 22 (6): 834. [PMID:34712358]
3. Liu K, Zhu C, Liang Y, Min D, Jin Z, Sun X. (2025) Discovery of a Novel 1,4-Benzodiazepine Derivative as a Highly Selective ANXA3 Degrader for the Treatment of Triple-Negative Breast Cancer. J Med Chem, 68 (5): 5358-5381. [PMID:40013713]
4. Wu N, Liu S, Guo C, Hou Z, Sun MZ. (2013) The role of annexin A3 playing in cancers. Clin Transl Oncol, 15 (2): 106-10. [PMID:23011854]
5. Zhou T, Li Y, Yang L, Tang T, Zhang L, Shi J. (2017) Annexin A3 as a Prognostic Biomarker for Breast Cancer: A Retrospective Study. Biomed Res Int, 2017: 2603685. [PMID:28497041]

References

1. Liang Y, Min D, Fan H, Liu K, Tu J, He X, Liu B, Zhou L, Liu S, Sun X. (2023)
Discovery of a first-in-class ANXA3 degrader for the treatment of triple-negative breast cancer.
Acta Pharm Sin B, 13 (4): 1686-1698. [PMID:37139408]

2. Liu C, Li N, Liu G, Feng X. (2021)
Annexin A3 and cancer.
Oncol Lett, 22 (6): 834. [PMID:34712358]

3. Liu K, Zhu C, Liang Y, Min D, Jin Z, Sun X. (2025)
Discovery of a Novel 1,4-Benzodiazepine Derivative as a Highly Selective ANXA3 Degrader for the Treatment of Triple-Negative Breast Cancer.
J Med Chem, 68 (5): 5358-5381. [PMID:40013713]

4. Wu N, Liu S, Guo C, Hou Z, Sun MZ. (2013)
The role of annexin A3 playing in cancers.
Clin Transl Oncol, 15 (2): 106-10. [PMID:23011854]

5. Zhou T, Li Y, Yang L, Tang T, Zhang L, Shi J. (2017)
Annexin A3 as a Prognostic Biomarker for Breast Cancer: A Retrospective Study.
Biomed Res Int, 2017: 2603685. [PMID:28497041]